BMY Q1 2024 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q1 2024 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.9B+4.7% YoY

Gross Profit

$6.6B55.5% margin

Operating Income

$1.5B12.9% margin

Net Income

-$11.9B-100.4% margin

EPS (Diluted)

$-5.89

QoQ Revenue Growth

+3.4%

Cash Flow

Operating Cash Flow

$2.8B

Free Cash Flow

$2.5B

Stock-Based Comp.

$133M

Balance Sheet

Total Assets

$99.0B

Total Liabilities

$82.5B

Stockholders' Equity

$16.5B

Cash & Equivalents

$9.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.9B	$11.3B	+4.7%
Gross Profit	$6.6B	$6.5B	+1.1%
Operating Income	$1.5B	$2.5B	-37.4%
Net Income	-$11.9B	$2.3B	-626.6%

Revenue Segments

Eliquis

$3.7B31%

Opdivo

$2.1B18%

Revlimid

$1.7B14%

Pomalyst/Imnovid

$865M7%

Orencia

$798M7%

Yervoy

$583M5%

Sprycel

$374M3%

Reblozyl

$354M3%

Other Growth Brands

$319M3%

Other Legacy Brands

$228M2%

Abraxane

$217M2%

Opdualag

$206M2%

Zeposia

$110M1%

Breyanzi

$107M1%

Camzyos

$84M1%

Abecma

$82M1%

Sotyktu

$44M0%

Krazati

$21M0%

Geographic Segments

UNITED STATES

$8.5B71%

Rest Of World

$3.2B27%

Other Region

$199M2%